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Abstract Non-structural protein 3 (NS3) of the hepatitis C virus 
(HCV) has been shown to be a serine proteinase which cleaves 
the HCV polyprotein thus activating its replicative machinery. To 
characterize enzymatic activities of NS3 serine proteinase, the 
proteinase region was expressed in Eschevichia coli and purified. 
The purified proteinase specifically cleaved a purified fusion pro- 
tein sandwiching the NS5A15B cleavage sequence. In addition to 
serine proteinase inhibitors, some chelators also inhibited the 
cleavage activity. Metal ions were not required for its activity, 
suggesting that the proteinase may be a novel serine proteinase 
having a unique binding site for chelators. 
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1. Introduction 
Hepatitis C virus (HCV) is the major etiological agent of 
post-transfusion non-A, non-B hepatitis worldwide [1,2]. HCV 
infection results in mild and acute liver disease, but chronic 
infections are common and may eventually develop into cirrho- 
sis or hepatocellular carcinoma [3,4]. Although interferons are 
currently used for the treatment of chronic hepatitis, their effi- 
cacy is limited to a small portion of the patients owing to 
insufficient suppression of HCV replication [5]. Therefore an- 
other reliable anti-HCV agent is necessary to control HCV 
hepatitis. 
Experiments using recombinant DNA techniques have re- 
vealed that HCV has positive-strand RNA approximately 9400 
nucleotides long which codes a single polyprotein of about 3010 
amino acids [I ,2,669]. Since its genomic organization is similar 
to that of the flaviviruses and pestiviruses, HCV is classified as 
a member of the family flaviviridae [lo]. Following the 5’- 
untranslated region, the viral structural proteins are located at 
the amino- (N-) terminal region of the polyprotein in the order 
of core, El and E2. The replicative machinery is located in the 
carboxyl (C)-terminal region as non-structural proteins and the 
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gene order is NS2-NS3-NS4A-NS4B-NS5A-NS5B [I I]. After 
being translated as a precursor polyprotein, the structural pro- 
teins were shown to be processed by a host cell signal peptidase 
with no apparent involvement of virus-coded proteinases. 
In contrast to the cleavage of the structural proteins by the 
host enzyme, the non-structural proteins are released by the 
action of virus-coded proteinase. Amino acid sequence analysis 
of a number of different isolates of HCV showed that the NS3 
protein contained three highly conserved amino acid residues, 
His-1083, Asp-l 107, and Ser-1165, which are well known as a 
catalytic triad of the serine proteinase family [ 12,131. In fact. it 
was confirmed that the Ser-1165 in the NS3 protein was essen- 
tial to cleave the downstream portion of the polyprotein by 
using in vitro transcription-translation systems and some mam- 
malian cell culture systems [14-181. From these studies, the 
N-terminal region of the NS3 protein was shown to cleave the 
NS3/4A, NS4A/4B, NS4B/5A, and NS5Al5B junctions but not 
the NS2/3 junction [19]. Comparison of the sequences around 
each cleavage site revealed the unique substrate specificity of 
the proteinase: Cys or Thr at the Pl position, Ser or Ala at the 
Pl’ position, and Asp or Glu at the P6 position [16]. Further 
analysis revealed that cleavage at NS2-NS3 was mediated by 
a second proteinase encoded within a region composed of the 
C-terminal portion of the NS2 gene and the N-terminal portion 
of the NS3 gene. This enzyme was likely a zinc-dependent 
metallo-proteinase whose His-952 and Cys-993 were involved 
in catalysis [20.21]. This putative metallo-proteinase overlaps 
the NS3 serine proteinase and presumably works in a self- 
inactivating manner. 
Since the viral serine proteinase was thought to be an attrac- 
tive target for antiviral therapy, several assay systems of NS3 
proteinase using in vitro transcription-translation systems and 
some mammalian cell culture systems have already been devel- 
oped. It is important to develop an enzymatic assay system 
which displays clear activity of the enzyme to facilitate inhibitor 
screening. Aiming at establishing such an assay system, we have 
cloned original HCV proteinase genes from the HCV-positive 
serum of chronic hepatitis patients into a plasmid of E. coli, and 
have examined their ability to cleave a substrate fusion protein 
containing the NS5A/5B cleavage site between MBP and pro- 
tein A, expressed in identical cells. In the course of these stud- 
ies, we found some highly active NS3 clones which cleaved the 
protein substrate in E. coli (Yamada, K. et al., unpublished 
results). Using one such clone, D5 1, and the recombinant sub- 
strate described above, we succeeded in detecting sufficient 
NS3 proteinase activity for application to inhibitor screening 
in vitro. In this paper, we describe the establishment of the 
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enzymatic NS3 proteinase assay system and the characteristics 
of the NS3 proteinase which was investigated by this system. 
2. Experimental 
2.1. Construction of expression plasmids 
The cDNA fragment encoding amino acid residues 1050~1214 in the 
HCV polyprotein was isolated by PCR, using our newly obtained HCV 
cDNA clone, pWNHD51, as a template and was inserted into the 
expression plasmid pNH71 which contains 13 N-terminal amino acid 
leaders derived from a nitrile hydratase gene (Yamada, K., unpublished 
data). This leader sequence possesses a consecutive stretch of histidine 
residues that allows a fusion protein to be purified in a single step by 
metal chelating affinity chromatography. The resulting plasmid, 
pNHJ13-9, encodes a fusion protein of 178 amino acid residues (Fig. 
IA). In the same way, the expression plasmid pNHJ13-9A, which en- 
codes a mutant type proteinase in which Ser-1165 is substituted to Ala. 
was constructed by using pWNHD5lA as a template for PCR (Fig. 
IA). The details of the plasmids pWNHD51 and pWNHD5lA will be 
reported elsewhere. 
Expression plasmid pMCP1, which encodes the E. coli MBP and the 
Staphylococcus aureus protein A in tandem, is a derivative of pMAL-c2 
(New England BioLabs Inc., USA) and pRIT2. Plasmid pMCP1 alao 
contains multiple cloning sites of pUC19 between the MBP gene and 
protein A gene. Substrate expression plasmids, pMCP-34, pMCP-44, 
pMCP-45 and pMCP-C2, which encode fusion proteins containing 
appropriate amino acid sequences for the NS3 proteinase cleavage site 
between the MBP and protein A junctions (Fig. lB), were constructed 
by inserting corresponding sequences into pMCP1. 
2.2. Expression and purification of‘ HCV NS3 proteinase 
E. coli DH5 harboring plasmid pNHJ13-9 or pNHJ13-9A was cul- 
tured in LB broth and induction was performed by cultivation under 
isopropyl-1-thio-/?-o-galactopyranoside (IPTG) (0.5 mM final concen- 
tration) at 25°C for 18 h [22]. Cells were suspended in Tris/NaCl (50 
mM Tris-HCI (pH 7.5), 150 mM NaCI) containing 1 mM EDTA. I mM 
dithiothreitol and 5% glycerol and treated with lysozyme (120 mg/ml) 
for 30 min. After sonication on ice with a Sonifier 450 (Branson Sonic 
Power Co., USA), the supernatant was obtained by ultracentrifugation 
(200,000 x g for 30 min) and underwent buffer exchange with Buffer A 
(50 mM Tris-HCl (pH 7.5), 0.5 M NaCI, 10 mM imidazol, 5% glycerol 
and 0.05% Tween 20) using a P6-DG desalting column (Bio-Rad Lab- 
oratories Inc., USA). Then it was applied to His Bind Resin (Novagen) 
pre-treated with Ni’+ solution. The His-tag-conjugated HCV NS3 pro- 
teinase was purified according to the protocol of the supplier. The 
buffer of the final proteinase fraction was exchanged with Tris/NaCl 
containing 0.05% Tween 20 and 20% glycerol. 
2.3. Expression and pur$cation of substrates 
The recombinant cells harboring a substrate expression plasmid were 
cultured in LB broth and induction was performed by IPTG (0.8 mM) 
for 3 h at 37°C. The cells were collected and sonicated in buffer contain- 
ing 50 mM Tris-HCl (pH 7.9), 150 mM NaCl, 0.05% Tween 20, 1 mM 
PMSF, and 1 mM EDTA. The supernatant obtained by centrifugation 
(15,000 x g for 30 min) was loaded onto an IgG-Sepharose column (2 
ml) and the substrate was purified according to the instruction manual. 
The eluted substrates were dialyzed against TrislNaCl. 
2.4. Detection of the proteinase activity 
Purified enzyme (60 ng) was mixed with purified substrate (3.2 @g) 
in a reaction mixture (20~1) composed ofTris/NaCl and 10 mM dithio- 
threitol, and incubated at 37°C for 4 h. After incubation, the reaction 
was stopped by adding SDS-PAGE sample buffer and heating at IOO’C 
for 5 min. The digested pattern was analyzed by SDS-PAGE followed 
by staining with Coomassie Brilliant Blue R-250 (CBB R-250). The 
absorbance of the protein A band (29 kDa) and the MBP band (43 
kDa), produced by the cleavage reaction, and that of the remaining 
substrate band (67 kDa) were scanned by He/Ne laser at 632.8 nm with 
a densitometric scanner FAST SCAN (Molecular Dynamics. USA). On 
the basis of the data obtained, proteinase activity was calculated by 
determining the percentage of cleaved substrate. When effects of pro- 
teinase inhibitors were evaluated, the enzyme was pre-incubated with 
each inhibitor at an appropriate concentration in 18 ~1 of Tris/NaCl 
at 30°C for 30 min and 2 ~1 of the substrate containing 0.1 M dithio- 
threitol were added. The inhibitory effects were calculated by defining 
the density at 0 time as 0% and that at 4 h without an inhibitor as 
100%. The 50% inhibitory concentration (IC,,) for each inhibitor was 
calculated from these data. 
3. Results 
3.1. Expression and af$nity purification of recombinant HCV 
NS3 proteinases and substrates 
To detect NS3-specific proteolitic activity in vitro, we pre- 
pared a wild type and a mutant type of the enzyme (D5ldNS3S 
and DSldNS3A, respectively) and a substrate (MCP-C2) (Fig. 
1). 
D5 ldNS3S and D5 ldNS3A were purified to nearly homoge- 
neity by a single step of metal chelating affinity chromatogra- 
phy (Fig. 2A, lanes 1 and 2). The 2 1 -kDa bands were confirmed 
to be DSldNS3S or D5ldNS3A by Western blotting using 
anti-NS3 antibody (data not shown). As substrates, fusion pro- 
teins composed of MBP and protein A sandwiching the NS3/ 
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NS3/4A (MCP-34) ACMSADLEVVTKI-WVLVGGV 
NS4A/4B (MCP-44) EFDEMEEC/ASHLPYIE 
NS4B/SA (MCP-45) EDCSTPC/SGSWLRDV 
NSSA/SB (MCP-CZ) GDDIVCUSMSY 
Fig. 1. Structural organization of the constructs used to express HCV 
NS3 proteinases and their substrates in E. co/i. (A) The entire HCV 
polyprotein, made up of structural proteins (Core to E2) and non- 
structual proteins (NS2 to NS5B), is shown at the top. Constructs for 
the expression and purification of the NS3 proteinase are indicated with 
their coded region below the HCV polyprotein. A serine residue of the 
wild type enzyme (DSldNS3S) was replaced by alanine in a mutant 
enzyme (DSldNS3A). (B) Schematic representation of various recom- 
binant substrates containing a cleavage site of the NS3 proteinase. The 
indicated cleavage sequences, corresponding to the NS3/4A, NS4A/4B, 
NS4B/5A. NS5A/5B cleavage sites, were inserted between MBP and 
protein A. 
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Fig. 2. Detection of the HCV NS3 proteinase activity using purified enzymes and substrates. (A) Purified NS3 proteinases and their substrates 
expressed in E. coli. DSldNS3S and DSldNS3A were purified by metal chelating affinity chromatography (lanes 1 and 2, respecttvely). The 
recombinant substrates MCP-C2, MCP-34, MCP-44, and MCP-45 (shown in Fig. 1B) were purified by using IgG Sepharose resin (lanes 336, 
respectively). The bands of purified enzymes and substrates are indicated by arrows. (B) Detection of NS3 serine proteinase activity. DSldNS3S (lanes 
1, 3, 5, and 7) or DSldNS3A (lanes 2, 4, 6, and 8) was mixed with MCP-34 (lanes 1 and 2), MCP-44 (lanes 3 and 4) MCP-45 (lanes 5 and 6) or 
MCP-C2 (lanes 7 and 8) and the mixtures were incubated under the standard assay condition. Each sample was analyzed by SDS-PAGE followed 
by staining with CBB R-250. The MBP band (43 kDa) and the protein A band (29 kDa) produced by the cleavage are indicated by arrows. 
4A, NS4A/4B, NS4B15A or NS5A/5B cleavage site were puri- 
fied with IgG Sepharose resin (Fig. 2A, lanes 3-6). 
3.2. Detection of NS3 proteinase activity in vitro 
When the substrate MCP-C2 was mixed with wild type en- 
zyme DSldNS3S in the presence of 10 mM dithiothreitol, the 
enzyme specifically cleaved MCP-C2 to produce an MBP frag- 
ment and a protein A fragment (Fig. 2B, lane 7). However, 
when the mutant enzyme DSldNS3Awas mixed with MCP-C2, 
cleavage was not detected (Fig. 2B, lane 8). The purified NS3 
proteinase cleaved the substrate only by the wild type enzyme, 
suggesting that the cleavage did not result from contaminating 
bacterial proteinases. To confirm the NS3 proteinase activity, 
we determined the N-terminal amino acid sequence of the pro- 
tein A fragment produced in the reaction. The sequence was 
SMSY-, which was identical to the predicted one (Fig. 1B) [16], 
assuring the cleavage by HCV NS3 proteinase. 
To study the basic characteristics of the NS3 proteinase, we 
performed the reaction at various pHs. It was found that the 
enzyme was most reactive at pH 7.5. Its activity was mostly lost 
below pH 6.0 and above pH 9.0 as previously shown in bacu- 
lovirus expression system [23]. We also measured the enzyme 
activity at various temperatures. The activity was highest at 
37°C and considerably lost at 4°C (data not shown). 
When DSldNS3S or DSldNS3A was incubated with MCP- 
34, MCP-44, or MCP-45, which contain other cleavage se- 
quences (Fig. lB, Fig. 2A lanes 46) the cleavage were not 
observed (Fig. 2B, lanes l-6). Although slight cleavage of the 
Table 1 
Effects of different types of proteinase inhibitors on the ability of NS3 
proteinase to cleave the substrate containing NS5A/5B cleavage site 
Type of Inhibitor d 
target proteinase ;ZM) 
Ser PMSF 0.60 
APMSF 1.89 
Pefabloc/SC 0.45 
3,4-dichloroisocoumarin 0.03 
TLCK 0.15 
TPCK 0.03 
Chymostatin 0.71 
Antipain >l 
Leupeptin >l 
Sov bean trvusin inhibitor >2 mg/ml 
CYS 
ASP 
E-64 .1 
Iodoacetamide 
Peustatin 
>l 
0.26 
>I 
Exb(amino) 
Metal10 
Bestatin >l 
EDTA 0.007 
EGTA 1.6 
CyDTA 0.007 
l,lO-Phenanthroline 0.26 
1,7-Phenanthroline >2 
“The IC,, values were calculated from dose-response curves involving 
at least three different concentrations. 
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Fig. 3. Study of the involvement of metal ions to the enzyme activity. (A) Effect of metal ions on the enzyme activity. Several metal ions of indicated 
concentrations were added to the assay mixture and the enzyme activity was measured under the standard assay condition. (B,C) Effect of metal 
ions on the enzyme pre-treated with EDTA or l,lO-phenanthroline, respectively. The proteinase fraction treated with 0.2 mM EDTA (B) or 1 mM 
l,lO-phenanthroline (C) for 30 min were dialyzed against Tris/NaCl buffer containing 0.1% Tween 20. The enzyme activity was measured under the 
standard assay condition with or without metal ions. The cleavage activity is shown as a percentage of that without addition of metal ions. 
NS4Al4B site was shown, no digestion of the NS3/4A and 
NS4B/5A sites was detected by Western blotting analysis with 
the anti-MBP antibody (data not shown). 
3.3. Susceptibility to various proteinase inhibitors 
Up to now, there was no report in which effect of commercial 
available inhibitors was studierd in the purified enzymatic assay 
system. To characterize the enzymatic activity of DSldNS3S, 
the effect of various proteinase inhibitors was studied. The NS3 
proteinase has been demonstrated to be a serine proteinase by 
mutation analysis at Ser-1165 (Fig. 2) and its sequence homol- 
ogy with other serine proteinases, which was biochemically 
ascertained by the effectiveness of some serine proteinase inhib- 
itors (Table 1). In addition to PMSF, PefabloclSC, and 3.4- 
dichloroisocoumarin, which inhibit a wide range of serine pro- 
teinases, TLCK and TPCK effectively inhibited NS3 proteinase 
activity. Chymostatin, known as a competitive inhibitor of chy- 
motrypsin, weakly inhibited the NS3 proteinase, while antipain 
and leupeptin, which are known to be reversible competitive 
inhibitors of trypsin-like proteinases, did not decrease the activ- 
ity. 
Interestingly, in addition to some serine proteinase inhib- 
itors, chelators such as EDTA, CyDTA and l,lO-phenanthro- 
line, also inhibited the proteinase activity (Table 1). 1,7- 
Phenanthroline, a non-chelating analog of 1,l O-phenanthro- 
line, had no effect on the proteinase activity, suggesting impor- 
tance of the chelating portion of l,lO-phenanthroline. How- 
ever, among tetraacetic acid derivatives, EGTA showed only 
weak inhibition of the reaction while EDTA and CyDTA very 
efficiently inhibited it. 
3.4. Examination of the inhibitory effect of chelators 
The inhibition by some chelators raised two possibilities that 
a metal ion might be participating in the NS3 proteinase activity 
or that binding of chelators to the proteinase resulting in inhi- 
bition of the activity. In the former case, the NS3 proteinasc 
is classified as a metal (Ca2+)-activated serine proteinase, or 
Zn2’ is involved in the proteinase activity since the NS3 serine 
proteinase region is located within the zinc-dependent metallo- 
proteinase region responsible for processing at the NS2/3 site 
[20,21]. 
To study the contribution of metal ions to the proteinase 
activity, some metal ions (Mg2+, Ca2+, Mn2’, Zn2+, and Ni2’) 
were added to the reaction mixture. The enzyme was not acti- 
vated by any metal ions, and was inhibited by Zn2’ and Ni” 
even at the low concentration of 0.01 mM (Fig. 3A). To further 
examine the effect of metal ions on the enzyme activity, the 
enzyme activity was measured after removal of possibly pre- 
existing metal ions from the enzyme fraction. The enzyme was 
treated with 0.2 mM EDTA or 1 mM l,lO-phenanthroline and 
dialyzed against Tris/NaCl containing 0.1% Tween 20. It was 
found that the proteinase activity was restored after dialysis 
(approximately 80% or 50% of the original enzyme activity, 
when treated with EDTA or 1, lo-phenanthroline, respectively). 
Even when the metal ions were added to these enzymes, no 
activation was observed (Mg’+, Ca2’ and Mn”) and similar 
inhibition to Fig. 3A was shown (Zn” and Ni2’) in Fig. 3B and 
C. Furthermore, when the enzyme inactivated by treatment 
with EDTA or 1, IO-phenanthroline was diluted ten times with 
metal-free water, the enzyme activity was recovered to the con- 
trol level without supplement of metal ions (data not shown). 
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These results show that metal ions are not involved in the 
proteinase activity and that the chelators themselves inhibit the 
NS3 serine proteinase by binding to the enzyme as a reversible 
inhibitor, not by removing metal ions from the enzyme. 
4. Discussion 
To establish an enzymatic assay system, we selected the 
DSldNS3S clone, which covers the region 1050-1214 of the 
NS3 protein, from the results of deletion analyses of our orig- 
inal HCV NS3 proteinase clones. This clone expressed the high- 
est ability to cleave a recombinant substrate containing the 
NS5A/5B cleavage site in an E. coli co-expression system 
(Yamada, K. et al., unpublished results). By using this enzyme, 
we succeeded in detecting enzymatic cleavage activity in vitro 
at the level of CBB R-250 staining. 
Our in vitro assay system revealed that the peptide sequence 
of 11 amino acids around the NS5A15B site was a favorable 
substrate for trans cleavage by the NS3 proteinase, while those 
of the other sites were hardly cleaved at all (Fig. 2B). These 
results confirmed previous reports suggesting that in vivo cleav- 
ages by the NS3 proteinase could be separated into two types: 
cleavages which require NS4A as a cofactor (NS3/4A, NS4A/ 
4B, and NS4B/SA sites) and one which does not (NS5A/5B site) 
[24-271. It was also presented that NS4A might cause the en- 
zyme to change substrate specificity. The effect of NS4A on the 
NS3 proteinase activity remains to be studied in our enzymatic 
assay system. 
We examined the effect of well-known proteinase inhibitors 
by the established in vitro assay system. The NS3 proteinase 
has been predicted to be a chymotrypsin-like serine proteinase 
based on the sequence homology around the active center [13]. 
Supporting data were reported using an in vitro transcription 
and translation system, in which only the chymotrypsin-specific 
inhibitors TPCK, chymostatin and PefabloWSC inhibited the 
proteinase activity [28]. Although it was reported that 300 PM 
of TLCK (effective against trypsin-like serine proteinases) did 
not inhibit the activity [28], we found that the same concentra- 
tion of TLCK inhibited 67% of the activity in our assay system. 
As shown in this study, some chelators also inhibited the en- 
zyme activity (Table 1, Fig. 3) in spite of the observation by 
Hahm et al. that 2 mM of EDTA did not show any inhibitory 
effect. The contradiction to the data of Hahm et al. seems to 
be derived from the differences of the purity and the conditions 
of the assay systems. These inhibition profile might reflect the 
existence of a unique active site pocket, which would define the 
unique substrate specificity (requirement of a cysteine residue 
at the Pl position, especially in the NS5A/5B cleavage site 
[29,30]) of the enzyme. 
Although the chelating portion of 1, lo-phenanthroline 
seemed to be involved in the inhibition, it was shown that the 
chelator itself inhibited the enzyme activity in a manner inde- 
pendent of metal ions, such as by direct binding to the enzyme 
(Fig. 3). Among EDTA, CyDTA and EGTA, which contain 
tetraacetic acid in the molecules, only the former two chelators 
efficiently inhibited the enzyme activity (Table 1). Considering 
that the whole structure of EDTA is identical to the part of 
CyDTA, it is suggested that the structure has a suitable size and 
shape for binding to the enzyme. It is reported that the mode1 
of the specificity pocket of the enzyme includes Lys-1162 and 
Arg-1181 [31]. It could be speculated that negative charges of 
41 
EDTA/CyDTA or electron pairs of 1, lo-phenanthroine might 
interact with the side chains of such amino acids and thus 
inhibit the enzyme activity. Alternatively, these inhibitors might 
attach to a distinct site away from the active center, change the 
tertiary structure of the enzyme, and allosterically render it 
inactive. Since the purified recombinant NS3 proteinase has a 
relatively small molecular size compared to other proteinases, 
X-ray crystallographical analysis would also be useful to eluci- 
date the tertiary structure of this enzyme which possesses 
unique substrate specificity and sensitivity to chelators. 
Our enzymatic system, established for assay of the HCV NS3 
proteinase which is an attractive target for anti-HCV agents, 
provides a simple and clear strategy for the first screening of 
anti-HCV reagents. Considering the unique characteristics of 
HCV NS3 proteinase described in this report, specific inhib- 
itors against the proteinase could be identified in this system. 
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